Biomarkers in Toxicology and Drug Safety Assessment
Biomarkers have become indispensable tools in toxicology and drug safety assessment, providing measurable indicators of biological processes, pathogenic responses, or pharmacologic effects. Their use enhances the sensitivity and specificity of toxicity detection, facilitates early identification of adverse effects, and supports mechanistic understanding of drug action.
Biomarkers can be classified into several types: diagnostic, prognostic, predictive, pharmacodynamic, and safety biomarkers. In toxicology, safety biomarkers are particularly valuable for detecting organ-specific injury, inflammation, oxidative stress, or cellular dysfunction before irreversible damage occurs. Examples include liver enzymes (ALT, AST), kidney injury molecule-1 (KIM-1), and cardiac troponins.
Modern biomarker discovery leverages omics technologies—genomics, transcriptomics, proteomics, metabolomics—and bioinformatics to identify molecular signatures associated with toxicity. Integration of multi-omics data helps elucidate adverse outcome pathways and identify novel markers with translational potential.
In preclinical studies, biomarkers complement traditional endpoints like histopathology and clinical chemistry, allowing real-time monitoring of drug effects and non-invasive sampling. Their application extends to dose optimization, safety margin estimation, and patient stratification in clinical trials.
Regulatory agencies encourage biomarker qualification and incorporation into drug development plans. Validated biomarkers improve risk assessment, reduce animal use, and facilitate personalized medicine approaches.
Challenges include establishing biomarker specificity, sensitivity, reproducibility, and standardization of assays. Continuous research and collaboration among academia, industry, and regulators are essential to advance biomarker utility in toxicology.